» Articles » PMID: 37457128

Remodeling the Tumor Microenvironment to Overcome Treatment Resistance in HPV-negative Head and Neck Cancer

Overview
Date 2023 Jul 17
PMID 37457128
Authors
Affiliations
Soon will be listed here.
Abstract

Despite intensive efforts and refined techniques, overall survival in HPV-negative head and neck cancer remains poor. Robust immune priming is required to elicit a strong and durable antitumor immune response in immunologically cold and excluded tumors like HPV-negative head and neck cancer. This review highlights how the tumor microenvironment could be affected by different immune and stromal cell types, weighs the need to integrate metabolic regulation of the tumor microenvironment into cancer treatment strategies and summarizes the emerging clinical applicability of personalized immunotherapeutic strategies in HPV-negative head and neck cancer.

Citing Articles

Cancer-associated fibroblast-derived extracellular vesicles: regulators and therapeutic targets in the tumor microenvironment.

Xie J, Lin X, Deng X, Tang H, Zou Y, Chen W Cancer Drug Resist. 2025; 8:2.

PMID: 39935427 PMC: 11810458. DOI: 10.20517/cdr.2024.152.


The Three-Dimensional In Vitro Cell Culture Models in the Study of Oral Cancer Immune Microenvironment.

Abdolahinia E, Han X Cancers (Basel). 2023; 15(17).

PMID: 37686542 PMC: 10487272. DOI: 10.3390/cancers15174266.

References
1.
Wang L, Zhao X, Fu J, Xu W, Yuan J . The Role of Tumour Metabolism in Cisplatin Resistance. Front Mol Biosci. 2021; 8:691795. PMC: 8261055. DOI: 10.3389/fmolb.2021.691795. View

2.
Saddawi-Konefka R, OFarrell A, Faraji F, Clubb L, Allevato M, Jensen S . Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC. Nat Commun. 2022; 13(1):4298. PMC: 9314425. DOI: 10.1038/s41467-022-31941-w. View

3.
Gao Y, Zhou H, Liu G, Wu J, Yuan Y, Shang A . Tumor Microenvironment: Lactic Acid Promotes Tumor Development. J Immunol Res. 2022; 2022:3119375. PMC: 9207018. DOI: 10.1155/2022/3119375. View

4.
Farlow J, Birkeland A, Swiecicki P, Brenner J, Spector M . Window of opportunity trials in head and neck cancer. J Cancer Metastasis Treat. 2019; 5. PMC: 6638557. DOI: 10.20517/2394-4722.2018.100. View

5.
Choi J, Sebastian C, Ferrer C, Lewis C, Sade-Feldman M, LaSalle T . A unique subset of glycolytic tumour-propagating cells drives squamous cell carcinoma. Nat Metab. 2021; 3(2):182-195. PMC: 7954080. DOI: 10.1038/s42255-021-00350-6. View